Regression of Fatty Heart by Valsartan Therapy
Traditionally, obesity is considered an indirect cause of heart disease. Obese individuals typically present with a number of traditional Framingham risk factors (hypertension, dyslipidemia, and type 2 diabetes), predisposing them to heart attacks and subsequent heart failure. However, an emerging body of basic research revisits a hypothesis that fat is a direct cardiotoxin. Under healthy conditions, most triglyceride is stored in fatty tissue (adipocytes) while the amount of triglyceride stored in non-adipocyte tissues (such as the pancreas, the liver, skeletal muscle, and heart) is minimal and very tightly regulated. When this regulation is disrupted, intracellular triglyceride accumulates excessively in these organs ("steatosis") and has been implicated in activating adverse pathways which culminate in irreversible cell death ("lipotoxicity"), leading to several well-recognized clinical syndromes. These include non-alcoholic steatohepatitis (NASH), pancreatic beta-cell failure in type 2 diabetes, and dilated cardiomyopathy.
It has been recently observed that angiotensin II receptor blockers (ARBs) in addition to lowering blood pressure improve insulin sensitivity and decrease the risk for type 2 diabetes. This study will test the above theory in two study groups: Valsartan vs. Hydrochlorothiazide. We hypothesize that in obese humans with elevated myocardial triglycerides, blockade of the renin-angiotensin system (Valsartan group) will reduce myocardial fat with improvement of insulin sensitivity and heart function.
연구 개요
상세 설명
Basic science in animal models of genetic obesity have demonstrated that obese, insulin resistant animals have fatty hearts with reduced functional ability. More importantly, insulin sensitizing treatment of prediabetic rats delayed development of diabetes and improved heart function. A primary aim of our laboratory is to translate basic animal research, suggesting that excessive lipid accumulation in the myocardium is toxic, into the clinical setting using cardiac magnetic resonance imaging/spectroscopy technology. The results of this research may identify new biomarkers and drug targets to prevent cardiac disease in obese humans.
We used our novel in vivo magnetic resonance imaging and spectroscopy technique that enables quantification of triglyceride in human myocardium non-invasively, to demonstrate that obese humans like obese animals are characterized by elevated fat in myocardium. We hypothesize that in obese humans with elevated myocardial TG, blockade of the renin-angiotensin system will reduce myocardial fat with improvement of insulin sensitivity and heart function.
The aims of this study are to test if in obese people with impaired glucose tolerance (IGT):
Aim 1) Valsartan treatment will reduce myocardial fat and will improve heart geometry and function,
Aim 2) therapy with thiazide diuretic hydrochlorothiazide (HCTZ) treatment will elevate myocardial fat.
We are planning to test the action of Valsartan versus HCTZ as we expect that these drugs cause opposite metabolic effects. The landmark trial ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) has refocused attention to the thiazide-type diuretics as the first-line therapy for most patients with hypertension. Despite proven reduction in cardiovascular outcomes and low costs, there is on-going concern that one of the major side effect of the thiazides-glucose intolerance-may fuel the current U.S. epidemic of type 2 diabetes. Despite of efficacy and low cost thiazide diuretics are long known to cause insulin resistance, impaired glucose tolerance, and precipitation of overt diabetes.
연구 유형
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Texas
-
Dallas, Texas, 미국, 75390
- University of Texas Southwestern Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Prediabetic individuals with impaired glucose tolerance (2 hr postprandial glucose > 140mg/dL) or having 3 of 5 Metabolic Syndrome criteria:
- Fasting glucose > 100mg/dL;
- Waist circumference: men > 102cm, women > 88cm (confirmed with abdominal MRI);
- HDL: men < 40mg/dL, women < 50mg/dL;
- Triglycerides > 150mg/dL;
- Blood pressure > 130/80mmHg;
- Elevated hepatic triglycerides (>5.5%) and myocardial triglycerides (>0.6%)
- Elevated blood triglycerides >150mg/dL
- Age < 50 years
Exclusion Criteria:
- Type 2 Diabetes mellitus
- Prior exposure to renin system blockers or HCTZ
- BP > 160/100mmHg
- Claustrophobia
- Metallic implants in body
- Pregnant or planning to become pregnant
- Prior exposure to statin medications
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Valsartan
This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity.
It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month).
Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring.
During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits.
Visits 2 & 3 are needed for the adjustment of medication to the final dose level.
During visits 4 & 5, Dr. Price will check subject's status as they continue the medication.
In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
|
Valsartan 320mg PO daily for 8 months
다른 이름들:
|
|
활성 비교기: Hydrochlorothiazide
This arm will determine if thiazide diuretics elevate myocardial triglyceride levels.
It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month).
Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring.
During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits.
Visits 2 & 3 are needed for the adjustment of medication to the final dose level.
During visits 4 & 5, Dr. Price will check subject's status as they continue the medication.
In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
|
Hydrochlorothiazide 25mg PO daily for 8 months
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Myocardial triglyceride levels
기간: 8 months
|
8 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Hepatic triglyceride levels, insulin sensitivity, abdominal fat mass
기간: 8 months
|
8 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ronald G Victor, MD, University of Texas Southwestern Medical Center
- 연구 책임자: Lidia S Szczepaniak, PhD, University of Texas Southwestern Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IIRP Study US 73
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .